Tempest Therapeutics, Inc. insider trading
Every open-market purchase and sale by Tempest Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Tempest Therapeutics, Inc.’s insiders pay?
From March 20, 2013 to March 25, 2026, 20 insiders reported 57 open-market purchases and 1 sale not made under a pre-set plan in Tempest Therapeutics, Inc. Twelve months after each purchase was reported, the shares were +7.2% against the S&P 500 on average (median −72.0%), over 53 purchases with a full year of prices; 30% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 21, 2013 into $1,686 by November 2, 2026, −12.3% a year. It held shares 31% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $21,934 (+6.0% a year), and held throughout $61,591 (+14.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Aldrich Richard | Director | 22 | +67.2% (22) | 46% | 0 | — | June 3, 2016 |
| Dipp Michelle | Chief Executive Officer | 13 | −63.1% (13) | 8% | 0 | — | June 3, 2016 |
| Kozin Marc D | Director | 3 | −62.1% (3) | 0% | 0 | — | October 6, 2015 |
| Malley Thomas | Director | 3 | −56.3% (3) | 0% | 0 | — | April 9, 2015 |
| Westphal Christoph H | Director | 2 | +190.9% (2) | 100% | 0 | — | March 11, 2014 |
| Angel Matthew | CEO and President | 1 | — | — | 0 | — | March 25, 2026 |
| Bleck Christopher A | Chief Commercial Officer | 1 | +30.1% (1) | 100% | 0 | — | September 12, 2013 |
| Brady Stephen R | President and CEO | 1 | — | — | 0 | — | July 8, 2024 |
| Capello Jeffrey D | Director | 1 | −18.8% (1) | 0% | 0 | — | March 20, 2013 |
| Chapman Paul W.D. | Chief Operating Officer | 1 | −99.3% (1) | 0% | 0 | — | May 12, 2016 |
| Fisher Mary | Director | 1 | −72.9% (1) | 0% | 0 | — | September 11, 2015 |
| Harding David | Chief Commercial Officer | 1 | −68.1% (1) | 0% | 0 | — | April 14, 2015 |
| Longwood Fund, L.P. | 10% owner | 1 | −18.8% (1) | 0% | 0 | — | March 20, 2013 |
| Mcneely Theresa | EVP, Chief Comm. Officer | 1 | −68.0% (1) | 0% | 0 | — | April 9, 2015 |
| Stock Harald F. | Director | 1 | +30.1% (1) | 100% | 0 | — | September 12, 2013 |
| Trojanowski Justin | Corporate Controller | 1 | — | — | 0 | — | July 2, 2024 |
| Tzianabos Arthur | Chief Scientific Officer | 1 | +30.1% (1) | 100% | 0 | — | September 12, 2013 |
| Versant Venture Capital VI, L.P. | 10% owner | 0 | — | — | 1 | — | August 12, 2024 |
| Woiwode Thomas | Director | 1 | — | — | 0 | — | May 3, 2022 |
| Young Jeffrey E | Chief Financial Officer | 1 | −45.3% (1) | 0% | 0 | — | October 7, 2015 |
When several insiders traded Tempest Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Tempest Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged −1.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2016 | 2 buying | −44.6% | −23.9% | −96.8% |
| September 30, 2015 | 2 buying | +4.3% | −3.6% | −29.3% |
| April 30, 2015 | 6 buying | +12.1% | −43.4% | −67.2% |
| March 31, 2014 | 4 buying | −2.6% | +80.3% | +275.9% |
| September 30, 2013 | 5 buying | −18.1% | −18.6% | +48.0% |
| March 28, 2013 | 3 buying | +63.3% | +1.7% | −25.1% |